260 related articles for article (PubMed ID: 25297648)
21. Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII.
Ramamurthy RM; Rodriguez M; Ainsworth HC; Shields J; Meares D; Bishop C; Farland A; Langefeld CD; Atala A; Doering CB; Spencer HT; Porada CD; Almeida-Porada G
Front Immunol; 2022; 13():954984. PubMed ID: 36591257
[TBL] [Abstract][Full Text] [Related]
22. Correction of murine hemophilia A by hematopoietic stem cell gene therapy.
Moayeri M; Hawley TS; Hawley RG
Mol Ther; 2005 Dec; 12(6):1034-42. PubMed ID: 16226058
[TBL] [Abstract][Full Text] [Related]
23. Ultrasound-mediated gene delivery specifically targets liver sinusoidal endothelial cells for sustained FVIII expression in hemophilia A mice.
Lawton SM; Manson MA; Fan MN; Chao TY; Chen CY; Kim P; Campbell C; Cai X; Vander Kooi A; Miao CH
Mol Ther; 2024 Apr; 32(4):969-981. PubMed ID: 38341614
[TBL] [Abstract][Full Text] [Related]
24. Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice.
Kren BT; Unger GM; Sjeklocha L; Trossen AA; Korman V; Diethelm-Okita BM; Reding MT; Steer CJ
J Clin Invest; 2009 Jul; 119(7):2086-99. PubMed ID: 19509468
[TBL] [Abstract][Full Text] [Related]
25. Generation of a gene edited hemophilia A patient-derived iPSC cell line, YCMi001-B-1, by targeted insertion of coagulation factor FVIII using CRISPR/Cas9.
Sung JJ; Park S; Choi SH; Kim J; Cho MS; Kim DW
Stem Cell Res; 2020 Oct; 48():101948. PubMed ID: 32798916
[TBL] [Abstract][Full Text] [Related]
26. Expression of factor VIII by murine liver sinusoidal endothelial cells.
Do H; Healey JF; Waller EK; Lollar P
J Biol Chem; 1999 Jul; 274(28):19587-92. PubMed ID: 10391893
[TBL] [Abstract][Full Text] [Related]
27. Replacing bad (F)actors: hemophilia.
Doering CB; Spencer HT
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):461-7. PubMed ID: 25696895
[TBL] [Abstract][Full Text] [Related]
28. Role of bone marrow transplantation for correcting hemophilia A in mice.
Follenzi A; Raut S; Merlin S; Sarkar R; Gupta S
Blood; 2012 Jun; 119(23):5532-42. PubMed ID: 22368271
[TBL] [Abstract][Full Text] [Related]
29. Modeling of hemophilia A using patient-specific induced pluripotent stem cells derived from urine cells.
Jia B; Chen S; Zhao Z; Liu P; Cai J; Qin D; Du J; Wu C; Chen Q; Cai X; Zhang H; Yu Y; Pei D; Zhong M; Pan G
Life Sci; 2014 Jul; 108(1):22-9. PubMed ID: 24834837
[TBL] [Abstract][Full Text] [Related]
30. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.
Doering CB; Denning G; Dooriss K; Gangadharan B; Johnston JM; Kerstann KW; McCarty DA; Spencer HT
Mol Ther; 2009 Jul; 17(7):1145-54. PubMed ID: 19259064
[TBL] [Abstract][Full Text] [Related]
31. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
Front Immunol; 2020; 11():1293. PubMed ID: 32670285
[TBL] [Abstract][Full Text] [Related]
32. Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A.
Zanolini D; Merlin S; Feola M; Ranaldo G; Amoruso A; Gaidano G; Zaffaroni M; Ferrero A; Brunelleschi S; Valente G; Gupta S; Prat M; Follenzi A
Haematologica; 2015 Jul; 100(7):881-92. PubMed ID: 25911555
[TBL] [Abstract][Full Text] [Related]
33. Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream.
Neumeyer J; Lin RZ; Wang K; Hong X; Hua T; Croteau SE; Neufeld EJ; Melero-Martin JM
Blood Adv; 2019 Dec; 3(24):4166-4176. PubMed ID: 31851760
[TBL] [Abstract][Full Text] [Related]
34. Generation of Functional Liver Sinusoidal Endothelial Cells from Human Pluripotent Stem-Cell-Derived Venous Angioblasts.
Gage BK; Liu JC; Innes BT; MacParland SA; McGilvray ID; Bader GD; Keller GM
Cell Stem Cell; 2020 Aug; 27(2):254-269.e9. PubMed ID: 32640183
[TBL] [Abstract][Full Text] [Related]
35. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
36. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
37. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
Shi Q; Fahs SA; Wilcox DA; Kuether EL; Morateck PA; Mareno N; Weiler H; Montgomery RR
Blood; 2008 Oct; 112(7):2713-21. PubMed ID: 18495954
[TBL] [Abstract][Full Text] [Related]
38. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
39. An induced pluripotent stem cell-mediated and integration-free factor VIII expression system.
Yakura Y; Ishihara C; Kurosaki H; Kazuki Y; Komatsu N; Okada Y; Doi T; Takeya H; Oshimura M
Biochem Biophys Res Commun; 2013 Feb; 431(2):336-41. PubMed ID: 23291180
[TBL] [Abstract][Full Text] [Related]
40. A novel cell-sheet technology that achieves durable factor VIII delivery in a mouse model of hemophilia A.
Tatsumi K; Sugimoto M; Lillicrap D; Shima M; Ohashi K; Okano T; Matsui H
PLoS One; 2013; 8(12):e83280. PubMed ID: 24358271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
